In 1981, the National Cancer Institute undertook Phase I1 trials of interferon alfa-2a in patients with non-Hodgkin's lymphoma (including cutaneous T-cell lymphoma [CTCL]) and chronic lymphocytic leukemia (CLL). A dose of 50 X lo6 U/m2, three times per week, was used initially, then adjusted downwar
Monoclonal antibody (MoAb) therapy in non-Hodgkin's lymphomas
β Scribed by S.H. Lim; R.E. Marcus
- Publisher
- Elsevier Science
- Year
- 1992
- Tongue
- English
- Weight
- 902 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0268-960X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Antibody titers to EpsteinβBarr virus (EBV)βrelated antigens, i.e. viral capsid antigen (VCA), the D and R components of the early antigen (EA) complex and the EBVβassociated nuclear antigen (EBNA), were determined in a series of 86 patients with nonβHodgkin lymphomas and in 150 matched
Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have
The most common low grade B-cell non-Hodgkin's lymphomas are follicular lymphomas, and extranodal marginal zone lymphomas, also known as mucosa-associated lymphoid tissue (MALT) lymphomas. Localized presentations of follicular lymphoma occur in 20-30% of cases, while for MALT lymphomas, stage I-II d